Nigericin Na

SKU: orb1304550

Description

Nigericin sodium salt is a cationic ionophore antibiotic that activates the NLRP3 inflammasome and exhibits antibacterial activity against Gram-positive bacteria. It is widely used in research to study inflammasome biology, pyroptosis, and cellular ion transport in both cellular and animal models.

Research Area

Cell Biology

Key Properties

• CAS Number: 28643-80-3
• MW: 746.96
• Purity: >98%
• Formula: C₄₀H₅₇O₁₁Na
• SMILES: [Na+].[H][C@@]1(C[C@H](C)[C@@]([H])(O1)[C@]1(C)CC[C@@]([H])(O1)[C@]1(C)C[C@@H](C)[C@]2(O1)O[C@]([H])(C[C@@]1([H])CC[C@H](C)[C@@]([H])(O1)[C@@H](C)C([O-])=O)C[C@@H](OC)[C@H]2C)[C@@]1([H])O[C@@](O)(CO)[C@H](C)C[C@@H]1C
• Target: Ionophore
• Solubility: Soluble in DMSO (up to 50 mg/ml) or in Ethanol (up to 20 mg/ml).

Bioactivity

• Target IC50:
  4T1 cells:2.505 μM|SW116 cells:15.86 ± 0.18 μmol|S18 cells:2.03 ± 0.55 μM|S26 cells:4.77 ± 2.35 μM|HT29 cells:12.92 ± 0.25 μmol|MDA-MB-231 cells:2.881 μM
• In Vivo:
  METHODS: To detect anti-tumor activity in vivo, Nigericin sodium (2 mg/kg, subcutaneous injection every two days) and anti-PD-1 (250 μg/mouse, intraperitoneal injection once a week) were administered to BALB/c mice bearing triple-negative mammary adenocarcinoma tumor 4T1 for two weeks. RESULTS: PD-1 antibody alone did not show significant antitumor effects, while Nigericin sodium showed moderate antitumor effects.The combination of Nigericin sodium and anti-PD-1 almost completely inhibited tumor growth. METHODS: To investigate the effects of aging on inflammatory vesicle function, Nigericin sodium (0.005 mg/g, 250 μL) was administered as a single intraperitoneal injection once daily for seven days to influenza virus-infected BALB/c mice. RESULTS: Treatment with Nigericin sodium during influenza infection increased IL-1β production, increased capase-1 activity, and reduced morbidity and mortality in aged mice. During influenza virus infection, NLRP3 inflammatory vesicle activity is impaired in aged mice, and Nigericin sodium treatment rescues NLRP3 in aged hosts.
• In Vitro:
  METHODS: Triple-negative breast cancer cells MDA-MB-231 and 4T1 were treated with Nigericin sodium (0.25-20 μg/mL) for 24 h. The cell viability of the cells was detected by the MTS. RESULTS: Nigericin sodium dose-dependently inhibited the cell viability of MDA-MB-231 and 4T1 cells with IC50 of 2.881 μM and 2.505 μM, respectively. METHODS: Human lung cancer cells H460 were treated with Nigericin sodium (1 μM) for 24-48 h. Cell migration and invasion were detected by Transwell. RESULTS: Nigericin sodium significantly inhibited the migration and invasion of H460 cells.

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Antibiotic K178; Antibiotic X-464; Azalomycin M; PolyetherinA

Compound Identifiers

PubChem CID

16760591